ReviewWorld journal of gastrointestinal oncology2025
Treatment of recurrent hepatocellular carcinoma: The current standards and future perspectives.
Review in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MTA-NPs induce preferential cytotoxicity, oxidative DNA damage, and mitochondrial apoptosis in human Hep-G2 hepatocellular carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis.Biomedicines · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains one of the commonest cancers worldwide with an overall poor prognosis and survival rates. The rising incidence of liver disease, in particular non-alcoholic fatty liver disease, will account for a continued increase in the rates of liver cancer. The recurrence of HCC has been reported across the different etiologies of liver disease. Unlike primary HCC, there is no agreed consensus or guidance as to the optimum management of recurrent HCC (RHCC). Furthermore, the management of RHCC may prove more challenging compared to primary liver cancer, given the smaller residual liver volume and functions in settings following surgery or transplantation. Various modalities exist for the treatment of primary HCC including resection, liver transplantation, loco-regional and systemic therapies. Nevertheless, the role of such modalities remains unclear in the management of RHCC. In this article, we aim to review the different approaches of the current standards for the management of RHCC. We will also shed some light on the future perspectives in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.